Viggiano Pasquale, Santoro Michele, Boscia Giacomo, Porreca Annamaria, Borrelli Enrico, Bacherini Daniela, Lombardi Luca, Fumarola Rosita, Grassi Maria Oliva, Termite Alba Chiara, Reibaldi Michele, Alessio Giovanni, Sadda Srinivas, Boscia Francesco
Department of Translational Biomedicine Neuroscience, University of Bari "Aldo Moro", Bari, Italy.
Department of Human Sciences and Promotion of the Quality of Life, San Raffaele, Rome, Italy.
Acta Ophthalmol. 2025 Sep;103(6):e374-e384. doi: 10.1111/aos.17502. Epub 2025 Apr 17.
To evaluate the functional and morphological changes in patients with nAMD undergoing anti-VEGF therapy, focusing on the impact of concomitant diabetes with or without diabetic retinopathy.
This retrospective cohort study included 1096 eyes from 916 patients with nAMD treated at the retina department of the University of Bari between August 2017 and May 2023. Patients were divided into two groups: 892 eyes without diabetes and 204 eyes with diabetes. Best-corrected visual acuity (BCVA), central retinal thickness (CRT) and presence of intraretinal fluid (IRF), subretinal fluid (SRF), subretinal hyperreflective material (SHRM) and atrophy were assessed at baseline, post-loading phase and at 12-month follow-up.
At baseline, no significant differences were observed between groups. Post-loading phase, both groups showed significant improvements in BCVA and reductions in CRT. However, SRF persistence was notably more frequent in the diabetic group (64.2% vs. 27.2%, p < 0.001). At 12 months, SRF was present in 53.7% of the diabetic group compared to 34.9% of the non-diabetic group (p < 0.001). Diabetic patients with moderate diabetic retinopathy (DR) exhibited significantly higher SRF persistence compared to those with mild DR or no DR.
While anti-VEGF therapy improves visual and anatomical outcomes in both diabetic and non-diabetic patients with nAMD, diabetic patients, particularly those with more severe DR, experience a higher rate of persistence of SRF. This suggests a less than optimal anatomic treatment response and the potential need for more tailored management strategies in this patient population.
This retrospective cohort study investigated the impact of diabetes mellitus and diabetic retinopathy on neovascular age-related macular degeneration treatment outcomes. The study analysed 1096 eyes from 916 patients undergoing anti-VEGF therapy over 12 months.
为评估接受抗VEGF治疗的新生血管性年龄相关性黄斑变性（nAMD）患者的功能和形态学变化，重点关注合并糖尿病伴或不伴糖尿病视网膜病变的影响。
这项回顾性队列研究纳入了2017年8月至2023年5月在巴里大学视网膜科接受治疗的916例nAMD患者的1096只眼。患者分为两组：892只无糖尿病眼和204只糖尿病眼。在基线、负荷期后和12个月随访时评估最佳矫正视力（BCVA）、中心视网膜厚度（CRT）以及视网膜内液（IRF）、视网膜下液（SRF）、视网膜下高反射物质（SHRM）和萎缩的存在情况。
基线时，两组之间未观察到显著差异。负荷期后，两组的BCVA均有显著改善，CRT均降低。然而，糖尿病组SRF持续存在的情况明显更频繁（64.2%对27.2%，p<0.001）。在12个月时，糖尿病组53.7%的患者存在SRF，而非糖尿病组为34.9%（p<0.001）。中度糖尿病视网膜病变（DR）的糖尿病患者与轻度DR或无DR的患者相比，SRF持续存在的比例显著更高。
虽然抗VEGF治疗可改善糖尿病和非糖尿病nAMD患者的视力和解剖学结局，但糖尿病患者，尤其是那些患有更严重DR的患者，SRF持续存在的发生率更高。这表明解剖学治疗反应欠佳，且该患者群体可能需要更具针对性的管理策略。
这项回顾性队列研究调查了糖尿病和糖尿病视网膜病变对新生血管性年龄相关性黄斑变性治疗结局的影响。该研究分析了916例接受抗VEGF治疗超过12个月的患者的1096只眼。
